No quarterly revenue total was found in Aprea Therapeutics, Inc.'s SEC filings.
Aprea Therapeutics, Inc. (APRE) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$3.7 million.
Revenue
—
Net income
$-4.81M
-61.8% vs year-ago quarter
Operating cash flow
$-3.73M
-17.5% vs year-ago quarter
Free cash flow
$-3.73M
-13.2% vs prior quarter
EPS
$-0.09
+80.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
14.19M
+124.9% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Doylestown, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1781983
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$5.2M | -$4.0M | -$3.4M | -$2.6M | -$3.1M |
| Net income | -$4.8M | -$3.6M | -$3.3M | -$2.5M | -$3.0M |
| Diluted EPS | -$0.09 | -$0.07 | -$0.22 | -$0.32 | -$0.47 |
| Operating cash flow | -$3.7M | -$3.3M | -$2.8M | -$3.0M | -$3.2M |
| Free cash flow | -$3.7M | -$3.3M | — | — | — |
| Total assets | $38.8M | $42.3M | $47.6M | $15.9M | $14.3M |
| Stockholders' equity | $34.1M | $38.5M | $41.6M | $12.4M | $10.9M |
| Cash and investments | $37.8M | $41.2M | $46.5M | $14.6M | $13.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Aug 28, 2026 | Aug 28, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 23, 2026 | Jul 23, 2026 |
All 446 Aprea Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.